Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Paula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, howev...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-05-01
|
Series: | Clinical Interventions in Aging |
Subjects: | |
Online Access: | https://www.dovepress.com/efficacy-and-safety-of-risedronate-150-mg-once-a-month-in-the-treatmen-peer-reviewed-article-CIA |
id |
doaj-2e882e93e2ed4f66b1cbb41c040349be |
---|---|
record_format |
Article |
spelling |
doaj-2e882e93e2ed4f66b1cbb41c040349be2020-11-24T23:06:42ZengDove Medical PressClinical Interventions in Aging1178-19982009-05-01Volume 42072133092Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPaula RackoffPaula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.Keywords: osteoporosis, fracturehttps://www.dovepress.com/efficacy-and-safety-of-risedronate-150-mg-once-a-month-in-the-treatmen-peer-reviewed-article-CIArisedronatepostmenopausal osteoporosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Paula Rackoff |
spellingShingle |
Paula Rackoff Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis Clinical Interventions in Aging risedronate postmenopausal osteoporosis |
author_facet |
Paula Rackoff |
author_sort |
Paula Rackoff |
title |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis |
title_short |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis |
title_full |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis |
title_fullStr |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis |
title_full_unstemmed |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis |
title_sort |
efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis |
publisher |
Dove Medical Press |
series |
Clinical Interventions in Aging |
issn |
1178-1998 |
publishDate |
2009-05-01 |
description |
Paula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.Keywords: osteoporosis, fracture |
topic |
risedronate postmenopausal osteoporosis |
url |
https://www.dovepress.com/efficacy-and-safety-of-risedronate-150-mg-once-a-month-in-the-treatmen-peer-reviewed-article-CIA |
work_keys_str_mv |
AT paularackoff efficacyandsafetyofrisedronate150mgonceamonthinthetreatmentofpostmenopausalosteoporosis |
_version_ |
1725621606512852992 |